A Bausch + Lomb drug from a 2025 acquisition missed primary and secondary goals of a Phase 2 test in glaucoma. Bausch now plans to develop this drug for geographic atrophy, aiming to succeed where Allergan, now an AbbVie subsidiary, fell short in the clinic.
The post Glaucoma Drug Fails Trial, But Bausch + Lomb Sees Opportunity in Another Eye Disease appeared first on MedCity News.
